# OnCo record paper-columbus-lancet-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-columbus-lancet-oncol-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-columbus-lancet-oncol-2018" ;
  schema:name "COLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma"@en ;
  schema:description "The third BRAF-MEK combination, encorafenib plus binimetinib, delayed progression more than vemurafenib and produced the longest median survival of any targeted regimen in BRAF-mutant melanoma, with less fever than dabrafenib-trametinib."@en ;
  schema:url <https://onco.cc/key-papers/paper-columbus-lancet-oncol-2018/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30142-6>, <https://pubmed.ncbi.nlm.nih.gov/29573941/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(18)30142-6> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Dummer R, Ascierto PA, Gogas HJ, et al." ;
  onco:cancers <https://onco.cc/cancers/braf-v600-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/vemurafenib/> ;
  onco:trials <https://onco.cc/trials/columbus/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .